AU2011217181A1 - Use of transforming growth factor - beta 1 (TGF-beta1) inhibitor peptides for the treatment of corneal fibrosis and/or haze - Google Patents

Use of transforming growth factor - beta 1 (TGF-beta1) inhibitor peptides for the treatment of corneal fibrosis and/or haze Download PDF

Info

Publication number
AU2011217181A1
AU2011217181A1 AU2011217181A AU2011217181A AU2011217181A1 AU 2011217181 A1 AU2011217181 A1 AU 2011217181A1 AU 2011217181 A AU2011217181 A AU 2011217181A AU 2011217181 A AU2011217181 A AU 2011217181A AU 2011217181 A1 AU2011217181 A1 AU 2011217181A1
Authority
AU
Australia
Prior art keywords
seq
tgf
peptide
fusion protein
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011217181A
Other languages
English (en)
Inventor
Javier Dotor De Las Herrerias
Miguel Jose Maldonado Lopez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Digna Biotech SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Digna Biotech SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL, Digna Biotech SL filed Critical Proyecto de Biomedicina CIMA SL
Publication of AU2011217181A1 publication Critical patent/AU2011217181A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2011217181A 2010-02-22 2011-02-21 Use of transforming growth factor - beta 1 (TGF-beta1) inhibitor peptides for the treatment of corneal fibrosis and/or haze Abandoned AU2011217181A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/709,895 2010-02-22
US12/709,895 US8158589B2 (en) 2003-08-22 2010-02-22 Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
PCT/EP2011/052543 WO2011101478A1 (en) 2010-02-22 2011-02-21 USE OF TRANSFORMING GROWTH FACTOR - BETA 1 (TGF-β1) INHIBITOR PEPTIDES FOR THE TREATMENT OF CORNEAL FIBROSIS AND/OR HAZE

Publications (1)

Publication Number Publication Date
AU2011217181A1 true AU2011217181A1 (en) 2012-09-06

Family

ID=43757920

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011217181A Abandoned AU2011217181A1 (en) 2010-02-22 2011-02-21 Use of transforming growth factor - beta 1 (TGF-beta1) inhibitor peptides for the treatment of corneal fibrosis and/or haze

Country Status (10)

Country Link
US (2) US8158589B2 (https=)
EP (1) EP2538962A1 (https=)
JP (1) JP2013520405A (https=)
CN (1) CN102791283A (https=)
AU (1) AU2011217181A1 (https=)
BR (1) BR112012020953A2 (https=)
CA (1) CA2790625A1 (https=)
MX (1) MX2012009748A (https=)
RU (1) RU2012140704A (https=)
WO (1) WO2011101478A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158103A1 (en) * 2011-11-23 2013-06-20 The Curators Of The University Of Missouri Method of Tissue-Selective Targeted Gene Transfer
ES2423382B1 (es) * 2012-02-16 2014-07-15 Consejo Superior De Investigaciones Científicas (Csic) Inhibidor de la produccion de endoglina soluble y su aplicacion en patologias donde la endoglina soluble tiene un efecto patogenico
WO2013148155A1 (en) * 2012-03-26 2013-10-03 Digna Biotech Usa, Llc Compositions and methods for the treatment of dry eye disease
WO2014028862A1 (en) 2012-08-17 2014-02-20 Cornell University Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
RU2016106641A (ru) * 2013-07-30 2017-09-01 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Терапевтические средства, направленные на ecm эндотелия роговицы
CA2927898C (en) * 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
WO2015072580A1 (ja) 2013-11-14 2015-05-21 学校法人同志社 細胞増殖促進または細胞障害抑制による角膜内皮治療薬
EP3125907A4 (en) 2014-04-01 2017-11-29 Cornell University Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
US11397182B2 (en) 2014-10-07 2022-07-26 Cornell University Methods for prognosing and preventing metastatic liver disease
US11971402B2 (en) 2015-04-24 2024-04-30 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
ES2965877T3 (es) * 2015-10-27 2024-04-17 Univ Taipei Medical Derivados de indolina para el tratamiento y/o la prevención de enfermedades fibróticas
JPWO2017110093A1 (ja) 2015-12-24 2018-10-11 学校法人同志社 ＴＧＦ−βシグナルに起因する障害を治療または予防するための医薬およびその応用
MX2018014256A (es) * 2016-05-20 2019-08-16 Harvard College Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
WO2019022152A1 (ja) 2017-07-26 2019-01-31 学校法人同志社 ＴＧＦ－βシグナルに起因する障害を治療または予防するための医薬およびその応用
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
GB201908012D0 (en) * 2019-06-05 2019-07-17 Io Biotech Aps TGF-Beta vaccine
RU2700941C1 (ru) * 2019-07-05 2019-09-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ РК" Минздрава России) Способ предупреждения развития помутнения роговицы при ее механических травмах
RU2701178C1 (ru) * 2019-07-10 2019-09-25 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ РК" Минздрава России) Способ ускорения заживления роговицы при ее механических травмах
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用
CN110862434B (zh) * 2019-10-28 2021-07-06 中山大学 一种可促进TGF-β1蛋白靶向降解的化合物及其制备方法与应用
JP2020073483A (ja) * 2019-10-30 2020-05-14 京都府公立大学法人 角膜内皮ｅｃｍ治療薬
EP4269429A4 (en) * 2020-12-23 2025-07-30 Korea Inst Sci & Tech NEW PEPTIDE CAPABLE OF INHIBITING TGF-BETA SIGNALING AND ITS UTILIZATION
CN115040535B (zh) * 2022-08-15 2022-12-16 华南理工大学 硫酸化透明质酸在制备预防角膜纤维化、角膜瘢痕滴眼液中的应用
WO2026027520A1 (en) 2024-07-30 2026-02-05 Disit Biotech, S.L. Method of preparing parenteral formulations and formulations prepared therefrom

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550022A (en) 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
JPH08151396A (ja) 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
AU5593398A (en) * 1996-12-05 1998-06-29 Alcon Laboratories, Inc. The use of inhibitors of tgf-beta's functions to ameliorate ocular pathology
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
WO2000037072A1 (en) 1998-12-22 2000-06-29 Alcon Laboratories, Inc. Use of inhibitors of gag synthesis for the treatment of corneal haze
AU1533402A (en) 2000-10-13 2002-04-22 Univ Johns Hopkins Plasminogen activator to prevent corneal and subepithelial haze after laser vision correction surgery
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
EP1974740A4 (en) * 2005-10-24 2010-09-01 Proyecto Biomedicina Cima Sl USE OF TGF-BETA1 INHIBITORY PEPTIDES IN THE PREPARATION OF AN IMMUNE RESPONSE MODULATING AGENT
US7582609B2 (en) * 2006-03-01 2009-09-01 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment

Also Published As

Publication number Publication date
CA2790625A1 (en) 2011-08-25
RU2012140704A (ru) 2014-03-27
US20120315256A1 (en) 2012-12-13
CN102791283A (zh) 2012-11-21
US20100222280A1 (en) 2010-09-02
JP2013520405A (ja) 2013-06-06
EP2538962A1 (en) 2013-01-02
US8158589B2 (en) 2012-04-17
BR112012020953A2 (pt) 2017-02-07
WO2011101478A1 (en) 2011-08-25
MX2012009748A (es) 2012-12-05

Similar Documents

Publication Publication Date Title
US20120315256A1 (en) Use of transforming growth factor - beta 1 (tgf-b1) inhibitor peptides for the treatment of corneal fibrosis and/or haze
US10463708B2 (en) Peptide for treating ocular diseases and composition for treating ocular diseases comprising same
JP6640311B2 (ja) 軟骨細胞の細胞外基質由来ペプチド
CN101252949A (zh) 促进上皮再生
CN100360174C (zh) 胸腺素β4(Tβ4)、类似物、异构体及其它衍生物在制备治疗眼睛和周围组织失调的药物中的应用
EP2478010B1 (en) Partial peptide of lacritin
EP3715451A2 (en) Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient
WO2012111877A1 (ko) Ｆｋ506 결합 단백질 융합 단백질을 함유하는 안과 질환 예방 및 치료용 점안제 조성물
WO2012111878A1 (ko) 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물
KR20220063190A (ko) 안과 장애의 치료 또는 예방에 사용하기 위한 제제
JP6440107B2 (ja) 細胞シートの製造方法、組成物、細胞培養補助剤、及び細胞培養方法
WO2021183407A1 (en) Norrin regulation of plasmalemma vesicle-associated protein and use to treat macular degeneration
CN102336812B (zh) 一种具有抑制血管生成活性的多肽
CN101503458B (zh) 预防和治疗血管新生的小分子多肽及其应用
JP2023546757A (ja) ペプチド製剤および眼科におけるその使用
EP4574211A2 (en) Compositions of growth factor for the treatment of eye disease
CN104371003A (zh) 预防和治疗炎症的小分子多肽及其应用
CN105017406B (zh) 一类新的具有神经保护功能的多肽
CN104861058A (zh) 一类新的具有神经保护功能的多肽
US20250161403A1 (en) Peptides and methods of use thereof in treating ocular disorders
HK40128523A (en) Compositions of growth factor for the treatment of eye disease
WO2022204331A1 (en) Compositions comprising branched kgf-2 derived peptides and methods for use in ocular treatment
CN104004057A (zh) 一类新的抑制新生血管的小肽及其应用
HK40023769A (en) Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient
HK1074577B (en) THE USE OF THYMOSIN β4 (Tβ4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING DISORDERS OF EYE AND THE SURROUNDING TISSUE

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application